Novartis (NVS) Reports In-Line Q3 EPS of $1.21; Guides FY15 Sales Growth

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/8/2026

1. LEVI
2. APLD
3. STZ
4. SPY
5. RMR
6. DVN
7. CRGY
8. ZETA
9. ARGX
10. GOOGL

Go back to Novartis (NVS) Reports In-Line Q3 EPS of $1.21; Guides FY15 Sales Growth

Novartis (NVS) Receives FDA Approval for Afinitor Disperz Labeling Amendment

January 26, 2015 2:17 PM EST

Novartis (NYSE: NVS) received FDA approval of a labeling revision for Afinitor Disperz (everolimus).

In a letter to Novartis (which is embedded below), the FDA stated: This Prior Approval supplemental new drug application revises the ADVERSE REACTIONS, Clinical Study Experience in Renal Angiomyolipoma with... More